Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Published:2019-01 Issue:1 Volume:20 Page:57-73
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Jackson Graham H,Davies Faith E,Pawlyn Charlotte,Cairns David A,Striha Alina,Collett Corinne,Hockaday Anna,Jones John R,Kishore Bhuvan,Garg Mamta,Williams Cathy D,Karunanithi Kamaraj,Lindsay Jindriska,Jenner Matthew W,Cook Gordon,Russell Nigel H,Kaiser Martin F,Drayson Mark T,Owen Roger G,Gregory Walter M,Morgan Gareth J

Funder

Cancer Research UK

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Evolutionary biology of high-risk multiple myeloma;Pawlyn;Nat Rev Cancer,2017

2. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group;Sonneveld;Blood,2016

3. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial;Boyd;Leukemia,2012

4. The genetic architecture of multiple myeloma;Morgan;Nat Rev Cancer,2012

5. Clonal competition with alternating dominance in multiple myeloma;Keats;Blood,2012

Cited by 265 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Maintenance Therapy in the Treatment of Newly Diagnosed Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial;The Lancet Haematology;2024-09

3. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies;Stem Cell Research & Therapy;2024-08-13

4. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm;Blood Cancer Journal;2024-08-12

5. Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs;Clinical and Experimental Medicine;2024-08-06